Caribou Biosciences to restructure operations
- Restructuring includes discontinuing clinical trials for vispa-cel and CB-011
- Estimated costs of $15M-$19M for restructuring
- Workforce reduction expected in Q4 2026
Every EDGAR filing for Caribou Biosciences, Inc. (CRBU), newest first, with AI summaries and stories.
Next: earnings expected ~Nov 9 · 10-Q expected ~Nov 9 (deadline Nov 16)
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
Ownership stake disclosure by BlackRock, Inc.
BlackRock, Inc., filed by
Timothy P Kelly, insider filing for CRBU
Timothy P Kelly, reporting
Barbara G Mcclung, planned sale of CRBU shares
Barbara G Mcclung, reporting
Timothy P Kelly, planned sale of CRBU shares
Timothy P Kelly, reporting
Timothy P Kelly, insider filing for CRBU
Timothy P Kelly, reporting
David Lee Johnson, insider filing for CRBU
David Lee Johnson, reporting